Methods for treating fibromyalgia syndrome

Abstract

The invention is directed to a method of treating fibromyalgia syndrome in a subject, comprising administering a therapeutically effective amount of a carbamoyl compound, or pharmaceutically acceptable salt thereof.

1 - 17 . (canceled) 
     
     
         18 . A method of ameliorating effects of fibromyalgia syndrome in a subject, comprising administering to a subject in need thereof a therapeutically effective amount of a compound having structural Formula (1) or a pharmaceutically acceptable salt thereof: 
       
         
           
           
               
               
           
         
         wherein,
 R is selected from the group consisting of hydrogen and lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy of 1 to 3 carbon atoms, nitro group, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms; 
 x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; 
 R 1  and R 2  can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, and cycloalkyl of 3 to 7 carbon atoms; or 
 R 1  and R 2  can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocyclic compound comprises 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, and the nitrogen atoms are not directly connected with each other or with the oxygen atom. 
 
       
     
     
         19 . The method of  claim 18 , wherein the compound having structural Formula (1) is an enantiomer substantially free of other enantiomers or an enantiomeric mixture wherein one enantiomer of the compound having structural Formula (1) predominates. 
     
     
         20 . The method of  claim 19 , wherein one enantiomer predominates to the extent of about 90% or greater. 
     
     
         21 . The method of  claim 20 , wherein one enantiomer predominates to the extent of about 98% or greater. 
     
     
         22 . The method of  claim 19 , wherein the enantiomer is (S) or (L) enantiomer as represented by Structural Formula (1a): 
       
         
           
           
               
               
           
         
       
     
     
         23 . The method of  claim 22 , wherein one enantiomer predominates to the extent of about 90% or greater. 
     
     
         24 . The method of  claim 23 , wherein one enantiomer predominates to the extent of about 98% or greater. 
     
     
         25 . The method of  claim 19 , wherein the enantiomer is (R) or (D) enantiomer, as represented by Structural Formula (l b): 
       
         
           
           
               
               
           
         
       
     
     
         26 . The method of  claim 25 , wherein one enantiomer predominates to the extent of about 90% or greater. 
     
     
         27 . The method of  claim 26 , wherein one enantiomer predominates to, the extent of about 98% or greater. 
     
     
         28 . The method of  claim 25 , wherein the enantiomer is (R)-(beta-amino-benzenepropyl)carbamate. 
     
     
         29 . The method of  claim 28 , wherein the enantiomer of (R)-(beta-amino-benzenepropyl)carbamate predominates to the extent of about 90% or greater. 
     
     
         30 . The method of  claim 29 , wherein the enantiomer of (R)-(beta-amino-benzenepropyl)carbamate predominates to the extent of about 98% or greater. 
     
     
         31 . A method of treating fibromyalgia syndrome, comprising administering a therapeutically effective amount of a compound having structural Formula (1) or a pharmaceutically acceptable salt thereof, to a mammal suffering from fibromyalgia syndrome and in need of treatment: 
       
         
           
           
               
               
           
         
         wherein,
 R is selected from the group consisting of hydrogen and lower alkyl of 1 to 8 carbon atoms, halogen selected from F, Cl, Br and I, alkoxy of 1 to 3 carbon atoms, nitro group, hydroxy, trifluoromethyl, and thioaikoxy of 1 to 3 carbon atoms; 
 x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; 
 R 1  and R 2  can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, and cycloalkyl of 3 to 7 carbon atoms; or 
 R 1  and R 2  can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocyclic compound comprises 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, and the nitrogen atoms are not directly connected with each other or with the oxygen atom. 
 
       
     
     
         32 . A compound having structural Formula (1) or a pharmaceutically acceptable salt thereof 
       
         
           
           
               
               
           
         
         wherein,
 R is selected from the group consisting of hydrogen and lower alkyl of 1 to 8 carbon, atoms, halogen selected from F, Cl, Br and I, alkoxy of 1 to 3 carbon atoms, nitro group, hydroxy, trifluoromethyl, and thioalkoxy of 1 to 3 carbon atoms; 
 x is an integer of 1 to 3, with the proviso that R may be the same or different when x is 2 or 3; 
 R 1  and R 2  can be the same or different from each other and are independently selected from the group consisting of hydrogen, lower alkyl of 1 to 8 carbon atoms, aryl, arylalkyl, and cycloalkyl of 3 to 7 carbon atoms; or 
 
         R 1  and R 2  can be joined to form a 5 to 7-membered heterocycle substituted with a member selected from the group consisting of hydrogen, alkyl, and aryl groups, wherein the heterocyclic compound comprises 1 to 2 nitrogen atoms and 0 to 1 oxygen atom, and the nitrogen atoms are not directly connected with each other or with the oxygen atom.